Trial Details
RECRUITINGBasic Information
| Clinical ID | c2228 |
|---|---|
| Identifier | NCT03816345 |
| Trial Title | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO |
| Trial URL | Visit Original Page |
Study Information
| Study Results | NO |
|---|---|
| Conditions | Autoimmune Disease|Crohn Disease|Dermatomyositis|Hematopoietic and Lymphoid Cell Neoplasm|Inflammatory Bowel Disease|Malignant Solid Neoplasm|Multiple Sclerosis|Psoriasis|Psoriatic Arthritis|Rheumatoid Arthritis|Sjogren Syndrome|Systemic Lupus Erythematosus|Systemic Scleroderma|Ulcerative Colitis |
| Interventions | PROCEDURE: Biospecimen Collection|DRUG: Cabozantinib|DRUG: Fluoropyrimidine|BIOLOGICAL: Ipilimumab|BIOLOGICAL: Nivolumab|DRUG: Platinum Compound|DRUG: Platinum Doublet |
Participant Information
| Sponsor | National Cancer Institute (NCI) |
|---|---|
| City | Birmingham |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE1 |
Time Information
| Start Date | 2019-07-16 |
|---|---|
| Primary Completion Date | 2028-03-30 |
| Completion Date | 2028-03-30 |